Wednesday, November 13, 2024
HomeTagsVTX3232

VTX3232

Ventyx Biosciences Starts Phase 2a Dosing of VTX3232 for Early Parkinson’s

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics